Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (hepatic stellate cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: amifampridine, nerispirdine, dalfampridine +3 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 1 Parkinson's papers of 14 | 0.91 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 4752
Sealed predictions
- KCND1 in dopamine neurons, braak-0.19 (p 0.630) → -0.27 (p 0.489)receipt 4758
Swarm cases
receipt 4758: KCND1 in dopamine neurons, braak
- power
- full sample -0.13 (p 0.615, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.22 (p 0.384, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.31 (p 0.211, n 18). could be the mix.
- skeptic
- leave-one-out range -0.24 to -0.04, sign flips 0; without severely affected donors -0.13 (p 0.615, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCND1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts